In ovarian cancer, the optimal cutpoint for percentage of genome-wide HRD-LOH that predicted response to PARP inhibitor therapy was ascertained to be 14% within the ARIEL2 trial [12]. This evidence concerns the gene PARP1 and ovarian cancer.